The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The UK injectable drug delivery market is set to grow at 8.80% CAGR through 2034, driven by rising obesity rates and the approval of weight-loss injectable.

Newsom’s insulin fail. A drive by California Gov. Gavin Newsom to make low-cost insulin by spending $100 million in state ...

In 2023, the global disposable pen injectors market is expected to be worth USD 25.5 billion. The market is expected to reach USD 54.4 billion by 2033, expanding at a 7.9% CAGR throughout the forecast ...

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes chronic abdominal pain.

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...

The insulins available without a prescription come in vials and pens that may need ... you’re looking to use OTC insulin, you may also want to consider Eli Lilly’s affordable options, which ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...